Infections following peripheral blood progenitor cell transplantation for lymphoproliferative malignancies: Etiology and potential risk factors

被引:37
作者
Ketterer, N
Espinouse, D
Chomarat, M
Dumontet, C
Moullet, I
Rieux, C
Neidhardt-Berard, EM
Bouafia, F
Coiffier, B
Salles, G
机构
[1] Ctr Hosp Lyon Sud, Hospices Civils Lyon, Hematol Serv, F-69310 Pierre Benite, France
[2] Univ Lyon 1, UPRES JE Hemopathies Lymphoide Malignes 1879, Pierre Benite, France
[3] Ctr Hosp Lyon Sud, Hospices Civils Lyon, Bacteriol Lab, Pierre Benite, France
关键词
D O I
10.1016/S0002-9343(98)00409-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
PURPOSE: We sought to describe the infections that occur after large-dose chemotherapy, which was followed by autologous peripheral blood progenitor cell transplantation, and to determine their risk factors. PATIENTS AND METHODS: We retrospectively analyzed the occurrence and the characteristics of infections in 277 consec utive patients who received intensive chemotherapy for non-Hodgkin's lymphoma (n = 207), Hodgkin's disease (n = 27), or multiple myeloma (n = 43) in a single institution. Conditioning regimens included total body irradiation in 47% of the cases. Infections occurring within the 30 days after transplant were defined as early infections, whereas infections after that time in patients who had achieved a neutrophil count greater than 1.0 x 10(9)/L (1,000 per mu L) were considered as late infections. RESULTS: Within the first 30 days, 172 patients had unexplained fever (62%); infections were documented in 83 patients (30%), most commonly bacteremia (57 patients). Late infections occurred in 64 (26%) of 244 evaluable patients and consisted mainly of varicella zoster virus infections (n = 36) and pneumonia (n = 16). Administration of total body irradiation (odds ratio (OR) = 2.50; 95% confidence interval (CI) 1.4 to 4.5; P = 0.002) and previous use of fludarabine (OR 2.5; CI 1.2 to 5.2; P = 0.02) and a diagnosis of myeloma (OR 2.6; CI 1.2 to 5.6; P = 0.04;) were significantly associated with late infections. CONCLUSIONS: This study confirms that infectious toxicity after peripheral blood progenitor cell transplantation is usually moderate, although bacteremia remains a serious problem. Late infections are encountered in about 25% of patients and are more common in those with myeloma, or those who received total body irradiation or fludarabine. Am I Med. 1999;106: 191-197. (C) 1999 by Excerpta Medica, Inc.
引用
收藏
页码:191 / 197
页数:7
相关论文
共 43 条
[31]  
PERREN TJ, 1988, AM J MED, V85, P99
[32]   A RANDOMIZED TRIAL COMPARING CEFTAZIDIME ALONE WITH COMBINATION ANTIBIOTIC-THERAPY IN CANCER-PATIENTS WITH FEVER AND NEUTROPENIA [J].
PIZZO, PA ;
HATHORN, JW ;
HIEMENZ, J ;
BROWNE, M ;
COMMERS, J ;
COTTON, D ;
GRESS, J ;
LONGO, D ;
MARSHALL, D ;
MCKNIGHT, J ;
RUBIN, M ;
SKELTON, J ;
THALER, M ;
WESLEY, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1986, 315 (09) :552-558
[33]  
ROBERTS MM, 1993, BONE MARROW TRANSPL, V12, P469
[34]   Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients [J].
Schmitz, N ;
Linch, DC ;
Dreger, P ;
Goldstone, AH ;
Boogaerts, MA ;
Ferrant, A ;
Demuynck, HMS ;
Link, H ;
Zander, A ;
Barge, A ;
Borkett, K .
LANCET, 1996, 347 (8998) :353-357
[35]  
SCHUCHTER LM, 1989, BLOOD, V74, P1424
[36]  
SEMPERE A, 1992, BONE MARROW TRANSPL, V10, P495
[37]   The biology and clinical uses of blood stem cells [J].
To, LB ;
Haylock, D ;
Simmons, PJ ;
Juttner, CA .
BLOOD, 1997, 89 (07) :2233-2258
[38]  
TO LB, 1992, BONE MARROW TRANSPL, V9, P277
[39]  
VALTEAU D, 1991, BONE MARROW TRANSPL, V7, P415
[40]  
VILLABLANCA JG, 1990, BONE MARROW TRANSPL, V6, P387